Kedrion Biopharma Supports the Rare Disease Community at the 75th Annual Bleeding Disorders Conference
Kedrion supported the Plasminogen Deficiency Foundation in a roundtable for patients with Congenital Plasminogen Deficiency.
Kedrion Biopharma Announces Support for the Immune Deficiency Foundation Research Grant Program for Second Consecutive Year
The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (PI),
Kedrion confirms its commitment against Rabies infections in the US
Distribution agreement with Kamada for KEDRAB® extended until March 2026
IPPC 2023: Kedrion alongside PPTA
The Congress brought together policymakers, stakeholders, patient groups and industry in Europe
Kedrion’s global portfolio expands to China to supply human Albumin
This is the first ever approval for a BPL product in China
2023 ISTH Congress, Kedrion confirms its commitment to rare and ultra-rare diseases
Kedrion Biopharma and BPL participated in the 2023 ISTH Congress.
The Fifth John Gorman Lectureship at the “Birth 2022 Congress”
These Conferences in Transfusion Medicine are made possible thanks to the unconditional support of Kedrion Biopharma
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025